Dendritic cells as therapeutic vaccines against cancer

Nature Reviews Immunology

Volumn 5, Issue 4, 2005, Pages 296-306

  Banchereau, Jacques ^a   Palucka, A Karolina ^a  

^a BAYLOR INSTITUTE FOR IMMUNOLOGY RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CANCER VACCINE; DENDRITIC CELL VACCINE; IMMUNOLOGICAL ADJUVANT;

ANTIGEN RECOGNITION; CANCER IMMUNOLOGY; CANCER IMMUNOTHERAPY; CANCER RELAPSE; CELL MATURATION; CELLULAR IMMUNITY; DENDRITIC CELL; EFFECTOR CELL; HUMAN; IMMUNE RESPONSE; IMMUNOGENICITY; IMMUNOLOGICAL TOLERANCE; MEMORY CELL; PRIORITY JOURNAL; REVIEW; T LYMPHOCYTE; TUMOR VOLUME; VACCINATION;

CANCER VACCINES; DENDRITIC CELLS; HUMANS; IMMUNE TOLERANCE; NEOPLASMS;

EID: 17144417748     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri1592     Document Type: Review

References (148)

1. Steinman, R. M. The dendritic cell system and its role in immunogenicity. Annu. Rev. Immunol. 9, 271-296 (1991). A comprehensive and excellent review of DC biology that laid the groundwork for current approaches to investigating DCs and their use as a therapy.
2. Banchereau, J. et al. Immune-biology of dendritic cells. Annu. Rev. Immunol. 18, 767-811 (2000).
3. Mellman, I. & Steinman, R. M. Dendritic cells: specialized and regulated antigen processing machines. Cell 106, 255-258 (2001).
4. + hematopoietic progenitors from human cord blood diffferentiate along two independent dendritic cell pathways in response to granulocyte-macrophage colony-stimulating factor plus tumor necrosis factor α: II. Functional analysis. Blood 90, 1458-1470 (1997).
5. Jego, G. et al. Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19, 225-234 (2003).
6. Fernandez, N. C. et al, DendrSic cells directly trigger NK cell functions: cross-talk relevant in innate anti-tumor immune responses in vivo. Nature Med. 5, 405-411 (1999).
7. Kadowaki, N. et al. Distinct cytokine profiles of neonatal natural killer T cells after expansion with subsets of dendritic cells. J. Exp. Med. 193, 1221-1226 (2001).
8. Nossal, G. J. Host immunobiology and vaccine development. Lancet 350, 1316-1319 (1997).
9. Davis, I. D., Jefford, M., Parente, P. & Cebon, J. Rational approaches to human cancer immunotherapy. J. Leukoc. Biol. 73, 3-29 (2003). A comprehensive and excellent review of the development of immunotherapy for cancer, including DC-based vaccination trials.
10. Gilboa, E., Nair, S. K. & Lyerly, H. K. Immunotherapy of cancer with dendritic-cell-based vaccines. Cancer Immunol. Immunother. 46, 82-87 (1998).
11. Lu, W., Arraes, L. C., Ferreira, W. T. & Andrieu, J. M. Therapeutic dendritic-cell vaccine for chronic HIV-1 infection. Nature Med. 10, 1359-1365 (2004).
12. Rosenberg, S. A., Yang, J. C. & Restifo, N. P. Cancer immunotherapy: moving beyond current vaccines, Nature Med, 10, 909-915 (2004).
13. Foley, E. J. Antigenic properties of methylcholanthrene-induced tumors in mice of the strain of origin. Cancer Res. 13, 835-837 (1953).
14. Dighe, A. S., Richards, E., Old, L. J. & Schreiber, R. D. Enhanced in vivo growth and resistance to rejection of tumor cells expressing dominant negative 1FN γ receptors. Immunity 1, 447-456 (1994),
15. Euvrand, S., Kanitakis, J. & Claudy, A. Skin cancers after organ transplantation. N. Eng. J. Med. 348, 1681-1691 (2003).
16. Hakim, F. T., Flomerfelt, F. A., Boyiadzis, M. & Gress, R. E. Aging, immunity and cancer. Curr. Opin. Immunol. 16, 151-156 (2004).
17. Steinman, R. M. & Mellman, I. Immunotherapy: bewitched, bothered, and bewildered no more. Science 305, 197-200 (2004).
18. Townsend, A. R., Gotch, F. M. & Davey, J. Cytotoxic T cells recognize fragments of the influenza nucleoprotein. Cell 42, 457-467 (1985).
19. Boon, T., Cerottini, J. C., Van den Eynde, B., van der Bruggen, P. & Van Pel, A. Tumor antigens recognized by T lymphocytes. Annu. Rev, Immunol. 12, 337-365 (1994).
20. Rosenberg, S. A. Cancer vaccines based on the identification of genes encoding cancer regression antigens. Immunol. Today 18, 175-182 (1997).
21. Pardoll, D.M. Cancer vaccines. Nature Med, 4, 525-531 (1998).
22. Gilboa, E. The makings of a tumor rejection antigen. Immunity 11, 263-270 (1999).
23. Finn, O:. J. Cancer vaccines: between the idea and the reality. Nature Rev. Immunol. 3, 630-641 (2003).
24. Antonia, S., Mule, J. J. & Weber, J. S. Current developments of immunotherapy in the clinic. Curr. Opin. Immunol. 16, 130-136 (2004).
25. Hsueh, E. C. & Morton, D. L. Antigen-based immunotherapy of melanoma: Canvaxin therapeutic polyvalent cancer vaccine. Semin. Cancer Biol. 13, 401-407 (2003).
26. Sondak, V. K. & Sosman, J. A. Results of clinical trials with an allogenic melanoma tumor cell lysate vaccine: Melacine, Semin. Cancer Biol. 13, 409-415 (2003).
27. Steinman. R. M., Hawiger, D. & Nussenzweig, M. C. Tolerogenic dendritic cells. Annu. Rev. Immunol. 21, 685-711 (2003). An outstanding review that summarizes studies on tolerogenic DCs, written by the researchers who were the first to propose and show that DCs can induce immune tolerance.
28. Caux, C., Dezutter-Dambuyant, C., Schmitt, D. & Banchereau, J. GM-CSF and TNF-α cooperate in the generation of dendritic Langerhans cells. Nature 360, 258-261 (1992).
29. Romani, N. et al. Proliferating dendritic cell progenitors in human blood. J. Exp. Med. 180, 83-93 (1994).
30. Sallusto, F. & Lanzavecchia, A. Efficient presentation of soluble antigen by cultured human dendritic cells is maintained by granulocyte/ macrophage colony-stimulating factor plus interleukin 4 and downregulated by tumor necrosis factor α. J. Exp. Med. 179, 1109-1118 (1994).
31. Shortman, K. & Liu, Y. J. Mouse and human dendritic cell subtypes. Nature Rev. Immunol. 2, 151-161 (2002). A comprehensive and excellent review that summarizes our current knowledge of subsets of DCs that have different biological functions.
32. + hematopoietic progenitors from human cord blood differentiate along two independent dendritic cell pathways in response to GM-CSF + TNF α. J. Exp. Med. 184, 695-706 (1996).
33. Siegal, F. P. et al. The nature of the principal type 1 interferon-producing cells in human blood. Science 284, 1835-1837 (1999).
34. Cella, M. et al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce high levels of type I IFN. Nature Med. 5, 919-923 (1999).
35. Kadowaki, N., Antonenko, S., Lau, J. Y. & Liu, Y. J. Natural interferon α/β-producing cells link innate and adaptive immunity. J. Exp. Med. 192, 219-226 (2000).
36. + T cells: a new role for plasmacytoid dendritic cells in adaptive immuntty. Blood 101, 3520-3526 (2003).
37. Randolph, G. J., Inaba, K., Robbiani, D. F., Steinman, R. M. & Muller, W. A. Differentiation of phagocytic monocytes into lymph node dendritic cells in vivo. Immunity 11, 753-761 (1999).
38. Chomarat, P., Banchereau, J., Davoust, J. & Palucka, A. K. IL-6 switches the differentiation of monocytes from dendritic cells to macrophages. Nature Immunol. 1, 510-514 (2000).
39. Peters, J. H. et al. Signals required for differentiating dendritic cells from human monocytes in vitro. Adv. Exp. Med. Biol. 329, 275-280 (1993).
40. Paquette, R. L. et al. Interferon-α and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J. Leukoc. Biol. 64, 358-367 (1998).
41. Luft, T. et al. Type I IFNs enhance the terminal differentiation of dendritic cells. J. Immunol. 161, 1947-1953 (1998).
42. Santini, S. M. et al. Type I interferon as a powerful adjuvant for monocyte-derived dendritic cell development and activity in vitro and in Hu-PBL-SCID mice. J. Exp. Med. 191, 1777-1788 (2000).
43. Blanco, P., Palucka, A. K., Gill, M., Pascual, V. & Banchereau, J. Induction of dendritic cell differentiation by IFN-α in systemic lupus erythematosus. Science 294, 1540-1543 (2001).
44. Chomarat, P., Dantin, C., Bennett, L., Banchereau, J. & Palucka, A. K. TNF skews monocyte differentiation from macrophages to dendritic cells. J. Immunol. 171, 2262-2269 (2003).
45. Mohamadzadeh, M. et al, Interleukin 15 skews monocyte differentiation into dendritic cells with features of Langerhans cells. J. Exp. Med. 194, 1013-1020 (2001).
46. Serfert, U. et al. An essential role for tripeptidyl peptidasein the generation of an MHC class I epitope. Nature Immunol. 4, 375-379 (2003).
47. - subclasses of dendritic cells direct the development of distinct T helper eels in vivo. J. Exp. Med. 189, 587-592 (1999).
48. Pulendran, B. et al. Distinct dendritic cell subsets differentially regulate the class of immune response in vivo. Proc. Natl Acad, Sci. USA 96, 1036-1041 (1999).
49. Pulendran, B. et al. Lipopolysaccharides from distinct pathogens induce different classes of immune responses In vivo. J. Immunol. 167, 5067-5076 (2001).
50. Rissoan, M. C. et al. Reciprocal control of T helper cell and dendritic cell differentiation. Science 283, 1183-1186 (1999).
51. Brocker, T. The role of dendritic cells in T cell selection and survival. J. Leukoc. Biol. 66, 331-335 (1999).
52. + T cells with regulatory properties by repetitive stimulation wih allogenec immature human dendritic cells. J. Exp. Med. 192, 1213-1222 (2000).
53. Dhodapkar, M. V., Steinman, R. M., Krasovsky, J., Munz, C. & Bhardwaj, N. Antigen-specific inhibition of effector T cell function in humans after injection of immature dendritic cells. J. Exp. Med. 193, 233-238 (2001).
54. Bonifaz, L. et al. Efficient targeting of protein antigen to the dendritic cell receptor DEC-205 in the steady state leads to antigen presentation on major histocompatibility complex class I products and peripheral CD8+ T cell tolerance. J. Exp. Med. 196, 1627-1638 (2002).
55. Bonifaz, L. C. et al. In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination. J. Exp. Med. 199, 815-824 (2004).
56. + regulatory T cells by antigen-processing dendritic cells, J. Exp. Med. 198, 235-247 (2003).
57. Nestle, F. O. et al. Vaccination of melanoma patients with peptide- or tumor lysate-pulsed dendritic cells. Nature Med. 4, 328-332 (1998).
58. Thurner, B.et al. Vaccination with Mage-3A1 peptide-pulsed mature, monocyte-derived dendritic cells expands specific cytotoxic T cells and induces regression of some metastases in advanced stage IV melanoma. J. Exp. Med. 190, 1669-1678 (1999).
59. Hsu, F. J. et al. Vaccination of patients with B-cell lymphoma using autologous antigen-pulsed dendritic cells. Nature Med. 2, 52-58 (1996).
60. Small, E. J. et al. Immunotherapy of hormone-refractory prostate cancer with antigen-loaded dendritic cells. J. Clin. Oncol. 18, 3894-3903 (2000).
61. Fong, L. et al. Altered peptide ligand vaccination with Flt3 ligand expanded dendritic cells for tumor immunotherapy, Proc. Natl Acad. Sci. USA 98, 8809-8814 (2001).
62. Banchereau, J. et al. Immune and clinical responses in patients wih metastatic melanoma to CD34+ progenitor-derived dendritic cell vaccine. Cancer Res. 61, 6451-6458 (2001).
63. Figdor, C. G., de Vries, I. J., Lesterhuis. W. J. & Melief, C. J. Dendritic cell immunotherapy: mapping the way. Nature Med. 10, 475-480(2004),
64. Jonuleit, H. et al. A comparison of two types of dendritic cell as adjuvants for the induction of melanoma-specific T-cell responses in humans following intranodal injection. Int. J. Cancer 93, 243-251 (2001).
65. Schuler-Thurner, B. et al. Rapid induction of tumor-specific type 1 T helper cells in metastatic melanoma patients by vaccination with mature, cryopreserved, peptide-loaded monocyte-derived dendritic cells. J. Exp. Med. 195, 1279-1288 (2002).
66. Jonuleit, H. et al. Pro-inflammatory cytokines and prostaglandins induce maturation of potent immunostimulatory dendritic cells under fetal calf serum-free conditions. Eur. J. Immunol. 27, 3135-3142 (1997).
67. Mailliard, R. B. et al. α-Type-1 polarized dendritic cells: a novel immunization tool with optimized CTL-inducing activity. Cancer Res. 64, 5934-5937 (2004).
68. Reis e Sousa, C. Dendritic cells as sensors of infection. Immunity 14, 495-498 (2001). This paper summarizes the interactions of DCs with pathogens, and it provides background and rationale for the use of microbial products for DC maturation,
69. Pasare, C. & Medzhitov, R. Toll-dependent control mechanisms of CD4 T cell activation. Immunity 21, 733-741 (2004).
70. Eriksson, U. et al. Dendritic cell-induced autoimmune heart failure requires cooperation between adaptive and innate immunity. Nature Med. 9, 1484-1490 (2003).
71. Kadowaki, N. et al. Subsets of human dendritic cell precursors express different Toll-like receptors and respond to different microbial antigens, J. Exp. Med. 194, 863-869 (2001).
72. Morse, M. A. et al. Migration of human dendritic cells after injection in patients with metastatic malignancies. Cancer Res. 59, 56-58 (1999).
73. Martin-Fontecha, A. et al. Regulation of dendritic cell migration to the draining lymph node: impact on T lymphocyte trafic and priming. J. Exp. Med. 198, 615-621 (2003).
74. Scandella, E., Men, Y., Gillessen, S., Forster, R. & Groettrup, M. Prostaglandin E2 is a key factor for CCR7 surface expression and migration of monocyte-derived dendritic cells. Blood 100, 1354-1361 (2002).
75. 2 regulates the migratory capacity of specific DC subsets. Blood 100, 1362-1372 (2002).
76. Sallusto, F. et al. Rapid and coordinated switch in chemokine receptor expression during dendritic cell maturation. Eur J. Immunol. 28, 2760-2769 (1998).
77. Fong, L., Brockstedt, D., Benike, C., Wu, L. & Engleman, E. G. Dendritic cells injected via different routes induce immunity in cancer patients. J. Immunol. 166, 4254-4259 (2001).
78. Mora, J. R. et al. Selective imprinting of gut-homing T cells by Peyer's patch dendritic cells. Nature 424, 88-93 (2003).
79. Muffins, D. W. et al. Route of immunization with peptide-pulsed dendritic cells controls the distribution of memory and effector T cells in lymphoid tissues and determines the pattern of regional tumor control. J. Exp. Med. 198, 1-13 (2003).
80. + progenitor-derived dendritic cell vaccine can lead to induction of T-cell immunity in patients with stage IV melanoma. J. Immunother. 26, 432-439 (2003).
81. + progenitor-derived dendritic cells. J. Exp. Med. 199, 1503-1511 (2004).
82. Masopust, D., Vezys, V., Marzo, A. L. & Lefrancois, L. Preferential localization of effector memory cells in nonlymphoid tissue. Science 291, 2413-2417 (2001).
83. Kaech, S. M., Wherry, E. J. & Ahmed, R. Effector and memory T-cell differentiation: implications for vaccine development. Nature Rev. Immunol. 2, 251-262 (2002).
84. Zinkernagel, R. M. On natural and artificial vaccinations. Annu. Rev. Immunol. 21, 515-546 (2003).
85. Zajac, A. J. et al. Viral immune evasion due to persistence of actuated T cells without effector function. J. Exp. Med. 188, 2205-2213 (1998).
86. Wherry, E. J., Blattman, J. N., Murali-Krishna, K., van der Most, R. & Ahmed, R. Viral persistence alters CD8 T-cell immunodominance and tissue distribution and results in distinct stages of functional impairment. J. Virol. 77, 4911-4927 (2003).
87. Wang, R. F., Wang, X., Atwood, A. C., Topalian, S. L. & Rosenberg, S. A. Cloning genes encoding MHC class II-restricted antigens: mutated CDC27 as a tumor antigen. Science 284, 1351-1354 (1999).
88. Salgaller, M. L., Marincola, F. M., Cormier, J. N. & Rosenberg, S. A. Immunization against epitopes in the human melanoma antigen gp100 following patient immunization wih synthetic peptides. Cancer Res. 56, 4749-4757 (1996).
89. Solinger, A. M., Ultee, M. E., Margoliash, E. & Schwartz, R. H. T-lymphocyte response to cytochrome c. I. Demonstration of a T-cell heteroclitic proliferative response and identification of a topographic antigenic determinant on pigeon cytochrome c whose immune recognition requires two complementing major histocompatibiltty complex-linked immune response genes. J. Exp. Med. 150, 830-848 (1979).
90. Parkhurst, M. R. et al. Improved induction of melanoma-reactive CTL with peptides from the melanoma antigen gp100 modified at HLA-A*0201-binding residues. J. Immunol. 157, 2539-2548 (1996).
91. Stuge, T. B. et al. Diversity and recognition efficiency of T cell responses to cancer. PLoS Med. 1, e28 (2004).
92. Zitvogel, L. et al. Eradication of established murine tumors using a novel cell-free vaccine: dendritic cell-derived exosomes. Nature Med. 4, 594-600 (1998).
93. Ribas, A., Butterfield, L. H., Glaspy, J. A. & Economou, J. S. Cancer immunotherapy using gene-modified dendritic cells. Curr. Gene Ther. 2, 57-78 (2002).
94. Boczkowski, D., Nair, S. K., Snyder, D. & Gilboa, E. Dendritic cells pulsed with RNA are potent antigen-presenting cells in vitro and in vivo. J. Exp. Med. 184, 465-472 (1996).
95. Regnault, A. et al. Fcγ receptor-mediated induction of dendritic cell maturation and major histocompatibility complex class I-restricted antigen presentation after immune complex internalization. J. Exp. Med. 189, 371-380 (1999).
96. Fong, L. & Engleman, E. G. Dendritic cells in cancer immunotherapy. Annu. Rev. Immunol. 18, 245-273 (2000).
97. Albert, M. L., Sauter, B. & Bhardwaj, N. Dendritic cells acquire antigen from apoptotic cells and induce class I-restricted CTLs. Nature 392, 86-89 (1998).
98. Berard, F. et al. Cross-priming of naive CD8 T cells against melanoma antigens using dendritic cells loaded with killed allogeneic melanoma cells. J. Exp. Med. 192, 1535-1544 (2000).
99. Neidhardt-Berard, E. M., Berard, F., Banchereau, J. & Palucka, A. K. Dendritic cells loaded with killed breast cancer cells induce differentiation of tumor-specific cytotoxic T lymphocytes. Breast Cancer Res. 6, R322-R328 (2004).
100. + regulatory T cells induced by an agonist self-peptide. Nature Immunol. 2, 301-306 (2001).
101. + regulatory T cells. Nature Immunol. 4, 330-336 (2003).
102. Chen, Y., Kuchroo, V. K., Inobe, J., Hafler, D. A. & Weiner, H. L. Regulatory T cell clones induced by oral tolerance: suppression of autoimmune encephalomyelitis. Science 265, 1237-1240 (1994).
103. + T-cell subset inhibits antigen-specific T-cell responses and prevents colitis. Nature 389, 737-742 (1997).
104. Roncarolo, M. G., Bacchetta, R., Bordignon, C., Narula, S. & Levings, M. K. Type 1 T regulatory cells, Immunol. Rev. 182, 68-79 (2001).
105. + T-cell-dependent immune defense of B16 melanoma. Cancer Res. 61, 8643-8646 (2001).
106. Sutmuller, R. P. et al. Synergism of cytotoxic T lymphocyte-associated antigen 4 blockade and depletion of CD25-regulatory T cells in antitumor therapy reveals alternative pathways for suppression of autoreactive cytotoxic T lymphocyte responses. J. Exp. Med. 194, 823-832 (2001).
107. + T cells in tumors from patients with early-stage non-small cell lung cancer and late-stage ovarian cancer. Cancer Res. 61, 4766-1772 (2001).
108. Viguier, M. et al. Foxp3 expressing CD4+CD25high regulatory T cells are overrepresented in human metastatic melanoma lymph nodes and inhibit the function of infiltrating T cells. J. Immunol. 173, 1444-1453 (2004).
109. + regulatory T cells and their ligands: implications for immunotherapy. Immunity 20, 107-118 (2004). This study was the first to show tumour-specific inducible regulatory T cells in humans.
110. Terabe, M. et al. NKT cell-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway. Nature Immunol. 1, 515-520 (2000).
111. Reg cells and describes early approaches to improve immunity to tumours by removal of these regulatory cells with cyclophosphamide. This strategy has been rediscovered recently and is the focus of several studies.
112. Ma, J. et al. Anti-tumor T cell response and protective immunity in mice that received sublethal irradiation and immune reconstitution. Eur. J. Immunol. 33, 2123-2132 (2003).
113. Asavaroengchai, W., Kotera, Y. & Mule, J. J. Tumor lysate-pulsed dendritic cells can elicit an effective antitumor immune response during early lymphoid recovery. Proc. Natl Acad. Sci. USA 99, 931-936 (2002),
114. +, 2H4+ suppressor-inducer T-cells. Cancer Res. 48, 1671-1675(1988).
115. Hoon, D. S., Foshag, L. J., Nizze, A. S., Bohman, R. & Morion, D. L. Suppressor cell activity in a randomized trial of patients receiving active specific immunotherapy with melanoma cell vaccine and low dosages of cyclophosphamide. Cancer Res. 50, 5358-5364 (1990).
116. Pardoll, D. & Allison, J. Cancer immunotherapy: breaking the barriers to harvest the crop. Nature Med. 10, 887-892 (2004).
117. Gabrilovich, D. Mechanisms and functional significance of tumour-induced dendritic-cell defects. Nature Rev. Immunol. 4, 941-952 (2004).
118. Marrack, P., Kappler, J. & Mitchell, T. Type I interferons keep activated T cells dive, J. Exp. Med. 189, 521-530 (1999).
119. Tough, D. F., Sun, S., Zhang, X. &, Sprent, J. Stimulation of naive and memory T cells by cytokines. Immunol. Rev. 170, 39-47 (1999).
120. Phan, G. Q., Wang, E. &, Marincola, F. M. T-cell-directed cancer vaccines: mechanisms of immune escape and immune tolerance. Expert Opin. Biol. Ther. 1, 511-523 (2001).
121. Lanzavecchia, A. & Sallusto, F. Regulation of T cell immunity by dendritic cells. Cell 106, 263-266 (2001),
122. Rossi, D. & Zlotnik, A. The biology of chemokines and their receptors, Annu. Rev. Immunol. 18, 217-242 (2000).
123. Sun, J. C. & Bevan, M. J. Defective CD8 T cell memory following acute infection without CD4 T cell help. Science 300, 339-342 (2003).
124. Shedlock, D. J. & Shen, H. Requirement for CD4 T cell help in generating functional CDS T cell memory. Science 300, 337-339 (2003).
125. + T-cell memory.
126. Northrop, J. K. & Shen, H. CD8+ T-cell memory: only the good ones last. Curr. Opin. Immunol. 16, 451-155 (2004).
127. Kronenberg, M. Toward an understanding of NKT cell biology: progress and paradoxes. Annu. Rev. Immunol. 19 Jan 2005 (doi:10.1146/annurev.immunol.23. 021704.115742).
128. Cerwenka, A. & Lanier, L. L. Natural killer cells, viruses and cancer. Nature Rev. Immunol. 1, 41-49 (2001).
129. Qin, Z. et al. B cells inhibit induction of T cell-dependent tumor immunity. Nature Med. 4, 627-630 (1998).
130. Harris, D. P. et al. Reciprocal regulation of polarized cytokine production by effector B and T cells. Nature Immunol. 1, 475-482 (2000).
131. Figdor, C. G., van Kooyk, Y. & Adema, G. J. C-type lectin receptors on dendritic cells and Langerhans cells. Nature Rev. Immunol. 2, 77-84 (2002).
132. Valladeau, J, et al. The monoclonal antibody DCGM4 recognizes Langerin, a protein specific of Langerhans cells, and is rapidly internalized from the cell surface. Eur. J. Immunol. 29, 2695-2704 (1999).
133. Valladeau, J. et al. Langerin, a novel C-type lectin specific to Langerhans cells, is an endocytic receptor that induces the formation of Birbeck granules.Immunty 12, 71-81 (2000).
134. Dzionek, A. et al. BDCA-2, BDCA-3, and BDCA-4: three markers for distinct subsets of dendritic cells in human peripheral blood. J. Immunol. 165, 6037-6046 (2000).
135. Dzionek, A. et al. BDCA-2, a novel plasmacytoid dendritic cell-specific type II C-type lectin, mediates antigen capture and is a potent inhibitor of interferon α/β induction. J. Exp. Med. 194, 1823-1834 (2001).
136. Albert, M. L. et al. Tumor-specific killer cells in paraneoplastic cerebellar degeneration. Nature Med. 4, 1321-1324 (1998).
137. Inaba, K., Metlay, J. R., Crowley, M. T. &, Steinman, R. M. Dendritic cells pulsed with protein antigens in vitro can prime antigen-specific, MHC-restricted Tcells in situ. J. Exp. Med. 172, 631-640 (1990).
138. Sornasse, T. et al. Antigen-pulsed dendritic cells can efficiently induce an antibody response in vivo. J. Exp. Med. 175, 15-21 (1992).
139. Zitvogel, L et al. Therapy of murine tumors with tumor peptide-pulsed dendritic cells: dependence on T cells, B7 costimulation, and T helper cell 1-associated cytokines. J. Exp. Med. 183, 87-97 (1996).
140. Celluzzi, C. M., Mayordomo, J. I., Storkus, W. J., Lotze, M. T. & Falo, L. D. Jr. Peptide-pulsed dendritic cells induce antigen-specific CTL-mediated protective tumor immunity. J. Exp. Med. 183, 283-287 (1996).
141. Nair, S. K., Snyder, D., Rouse, B. T. & Gilboa, E. Regression of tumors in mice vaccinated with professional antigen-presenting cells pulsed with tumor extracts. Int. J. Cancer 70, 706-715 (1997).
142. -) prolong cardiac allograft survival in nonimmunosuppressed recipients. Transplantation 62, 659-665 (1996).
143. Soumelis, V. et al. Human epithelial cells trigger dendritic cell mediated alergic inflammation by producing TSLP. Nature Immunol. 3, 673-680 (2002).
144. Scheibenbogen, C. et al. Phase 2 trial of vaccination with tyrosinase peptides and granulocyte-macrophage colony-stimulating factor in patients with metastatic melanoma. J. Immunother. 23, 275-281 (2000).
145. Cebon, J. et al. Two Phase I studies of low dose recombinant human IL-12 with Melan-A and influenza peptides in subjects with advanced malignant melanoma. Cancer Immun. 3, 7-20 (2003).
146. Soiffer, R. et al. Vaccination with irradiated autologous melanoma cells engineered to secrete human granulocyte-macrophage colony-stimulating factor generates potent antitumor immunity in patents with metastatic melanoma. Proc. Natl Acad. Sci. USA 95, 13141-13146 (1998).
147. Mitchell, M. S. et al. Phase I trial of large multivalent immunogen derived from melanoma lysates in patients with disseminated melanoma. Clin. Cancer Res. 10, 76-83 (2004).
148. Mersey, P. et al. Phase I/II study of treatment with dendritic cell vaccines in patients with disseminated melanoma. Cancer Immunol. Immunother. 53, 125-134 (2004).